Heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure (CHF) cases. Our understanding of the pathophysiology of the disease has improved, but pharmacological treatments with proven outcomes benefits in HFpEF have proved elusive thus far. Current clinical guidelines focus on the management of comorbidities with angiotensin-converting enzyme (ACE) inhibitors, beta blockers, and diuretics, but despite the long list of clinical trial failures, promising drugs are in Phase III trials.
- What are the treatment drivers and goals for HFpEF?
- What drug attributes are key influences, which have limited impact, and which are hidden opportunities?
- How do current therapies perform on key treatment drivers and goals for HFpEF?
- What are the prevailing areas of unmet need and opportunity in HFpEF?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European cardiologists for a hypothetical new HFpEF drug?
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 30 European cardiologists fielded in August 2019
Key companies: Novartis, Eli Lilly, Boehringer Ingelheim, AstraZeneca
KEY METRICS INCLUDED
- Target Product Profile (TPP) simulator based on conjoint analysis methodology.
- Stated versus derived importance of product attributes on prescribing behavior.
- Assessment of current drug performance against treatment drivers and goals.
- Physician perceptions of unmet needs in HFpEF and related indications.
- Analysis of remaining drug development opportunities.
Key drugs:ACE inhibitors, angiotensin II receptor blockers,beta blockers, calciumchannel blockers, diuretics, spironolactone, Entresto (sacubitril/valsartan)
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
- Heart Failure - Unmet Need - Detailed, Expanded Analysis Heart Failure: Preserved Ejection Fraction (US/EU)
Author(s): Kahkashan Resham, Ph.D
Kahkashan Resham is a senior research associate in the Cardiovascular, Metabolic and Renal disorders team at Decision Resources Group. Her current work is focused on writing treatment algorithm reports, key opinion leader identification, clinical trial pipeline pulls, as well as secondary research across multiple cardiovascular and metabolic indications.
Prior to joining DRG, Resham obtained her doctorate in Pharmacology from National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar, India. She completed her M. Pharm. from the NIPER Hyderabad and was awarded a gold medal for securing 1st rank in the Institute. She holds a bachelor’s degree in Pharmacy from Birla Institute of Technology, Ranchi, India. Resham has also published several peer-reviewed research articles in the area of drug metabolism, diabetes and chemotherapy-induced peripheral neuropathic pain.